Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S (ASND) is the issuer of ADRs for which T. Rowe Price Investment Management, Inc. reported 8,194,812 ADRs, or 12.4% of the class, as beneficially owned as of September 30, 2026. The adviser reported sole voting power over 7,767,048 ADRs and sole dispositive power over 8,194,812, with no shared voting or dispositive power, while expressly denying that it is the beneficial owner. T. Rowe Price Capital Appreciation Fund was identified as having an interest in 3,951,747 ADRs, representing 6.0% of the class, and rights to dividends and sale proceeds from the securities it holds.
Ascendis Pharma A/S (ASND) granted 28,030 warrants to certain employees on November 10, 2026. Each warrant confers the right to subscribe for one ordinary share at an exercise price of US $256.59 per share, equal to the closing price of the ordinary shares on the grant date.
Twenty-five percent of the warrants will vest on the one-year anniversary of the grant; the remaining 75% will vest at a rate of 1/36th per month from one year after the grant, subject to continued service. Earlier vesting may occur upon certain exit events. After the grant, warrants to subscribe for an additional 1,431,143 shares remained available for future grants by the board. Ascendis amended its Articles of Association to provide for the grant.
Ascendis Pharma A/S (ASND) reported third-quarter 2026 revenue of €370 million, compared with €214 million in Q3 2025. Commercial product revenue was €366 million, up 89% year over year. The increase in total revenue was primarily attributable to continued growth in YORVIPATH global sales. Operating profit was €125 million, versus €11 million, and net profit was €74 million, compared with a €61 million net loss.
For the first nine months of 2026, cash flows from operating activities were €463 million, compared with €20 million used in the same 2025 period. Ascendis attributed the improvement primarily to commercial revenue growth and €158 million of net proceeds from the sale of a PRV, partly offset by approximately €15 million of less favorable working-capital changes and higher interest and income taxes paid.
For TransCon CNP, Ascendis received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of orphan medicinal product designation. A final EC decision is expected in Q4 2026, and the first EU launch is planned in Germany in Q1 2027. Week 52 sentinel-cohort data in infants aged 0 to under 2 years showed stabilized or improved foramen magnum stenosis and increased linear growth; topline pivotal data are expected in Q3 2027.
Ascendis Pharma A/S (ASND) reported third-quarter 2026 revenue of €369.657 million, compared with €213.634 million in the same 2025 period; nine-month revenue was €955.543 million versus €472.632 million. Nine-month net profit was €910.283 million, compared with a €194.472 million loss in 2025. It included €679.587 million from recognition of previously unrecognized deferred tax assets and €158.067 million of other operating income from the priority review voucher sale, net of transaction costs. Nine-month operating cash flow was €462.754 million, and cash and equivalents were €964.364 million at September 30, 2026.
A global settlement and license agreement with BioMarin provides Ascendis a non-exclusive worldwide license for navepegritide-related products. Ascendis agreed to royalties on net sales of 20% in the U.S. and 18% in the European Union, South Korea and Brazil, from each country's first commercial sale through May 20, 2030. Under the Novo Nordisk termination terms, licenses for metabolic and cardiovascular products will revert to Ascendis, with no continuing financial obligations between the parties.
U.S. sales of YUVIWEL began in the second quarter of 2026. A European Medicines Agency committee recommended authorization, and a final European Commission decision was expected during Q4 2026. Subsequent to September 30, Ascendis repurchased 1,204,695 ordinary shares for approximately $273.4 million under its $400 million September program.
Ascendis Pharma A/S (ASND) said the European Medicines Agency’s Committee for Orphan Medicinal Products adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) to treat achondroplasia in children. If the European Commission adopts the opinion, the designation would provide 10 years of orphan market exclusivity.
The EMA’s Committee for Medicinal Products for Human Use has also issued a positive opinion recommending EU marketing authorization for children two years of age and older whose epiphyses are not closed. The Commission’s final decision on Ascendis’ application is expected during Q4 2026. If authorized, Ascendis expects its first EU launch, in Germany under the YUVIWEL brand, during Q1 2027.
Ascendis Pharma A/S's ownership disclosure lists FMR LLC and Abigail P. Johnson with the same beneficially owned amount: 3,425,993 shares, equal to 5.2% of the common stock class. FMR LLC reported sole voting power over 3,425,841 shares, while Abigail P. Johnson reported no voting power. Both reported sole dispositive power over 3,425,993 shares and zero shared voting or dispositive power.
Ascendis Pharma A/S (ASND) announced pooled kidney-function data for adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years. The company said the data demonstrated early, sustained, clinically meaningful improvements. The analysis combined Phase 2 PaTH Forward and Phase 3 PaTHway trial data.
The trials included 141 adults; the pooled kidney analysis covered 139 who received at least one dose, of whom 129 completed the final trial visit. The post-hoc analysis evaluated change from baseline in eGFR, the proportion with an eGFR increase of at least 5 mL/min/1.73 m², and 24-hour urinary calcium. Mean baseline eGFR was 69 (SD 17) mL/min/1.73 m², and eligibility required eGFR ≥30 mL/min/1.73 m². The trials had placebo-controlled periods through Weeks 4 and 26, followed by open-label extensions through Weeks 266 and 182, respectively. Results were presented at Kidney Week 2026.
Ascendis Pharma A/S (ASND) said the EMA’s CHMP adopted a positive opinion recommending EU marketing authorization for once-weekly TransCon CNP (navepegritide) to treat achondroplasia in children two years of age and older whose epiphyses are not closed. The application included data from three randomized, double-blind, placebo-controlled trials and up to three years of open-label extension data.
The European Commission’s final decision is expected during the fourth quarter of 2026. TransCon CNP was designated an orphan medicine during development, and the EMA will review whether that designation can be maintained. If authorized, Ascendis expects its first EU launch, under the YUVIWEL brand, in Germany during the first quarter of 2027.
Ascendis Pharma A/S (ASND) granted 35,890 warrants to certain employees on October 13, 2026. Each warrant gives the holder the right to subscribe for one ordinary share at an exercise price of US $223.21 per share.
Subject to earlier vesting upon certain exit events, 25% of the warrants vest on the first anniversary of the grant; the remaining 75% vest at a rate of 1/36th per month from one year after the grant, subject to continued service. The company amended its Articles of Association in connection with the grant. Afterward, warrants to subscribe for an additional 1,459,173 shares remained available for future grants.
Ascendis Pharma A/S (ASND) said its outstanding-warrant exercise window closed on September 29, 2026. During the window, the company registered aggregate share capital increases of nominal DKK 210,812 through the issuance of 210,812 ordinary shares against average cash consideration of approximately USD $123.36 per share, based on the DKK-USD exchange rate on September 29, 2026. Its aggregate share capital increased to nominal DKK 66,400,738, and its articles of association were amended accordingly.